A Single and Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics SCH 900931 in Healthy Adult Japanese Subjects.

Mode of Administration will be oral capsule. Part 1- Cohort 1: Rising single dose SCH900931 (Period 1:20mg, Period 2:100mg & Period 3:550mg). The duration of each Period will be 6 days, in between doses for Part 1 will be at least 7 days between Period 1 and Period 2 and at least 21 days between Period 2 and Period 3. Part 2- Cohort 2 & 3 : Rising multiple dose SCH900931 of 2 cohort in a parallel study design (Cohort 2: 150mg & Cohort 3:250mg). For Part 2, dosing will be once daily for 14 consecutive days for subjects in either Cohort 2 or Cohort 3. Subjects will participate only in Part 1 or in one of the 2 cohorts in Part 2. The first part of the study will determine PK dose proportionality by using 3 single doses. The second part of the study will allow for determination of steady-state PK and accumulation ratio by once daily administration for 14 days.